NCT07055230Completed
Interest of IgE Directed Against Recombinant Antigens of Aspergillus Fumigatus in the Diagnosis of Allergic Bronchopulmonary Aspergillosis (ABPA)
Study of the Interest of IgE Directed Against Recombinant Antigens of Aspergillus Fumigatus in the Diagnosis of Allergic Bronchopulmonary Aspergillosis (ABPA) in Patients With Chronic Obstructive Bronchopulmonary Disease
Source: ClinicalTrials.gov · Last updated 8 Jul 2025
Brief summary (registry, in English)
Allergic Bronchopulmonary Aspergillosis is a rare pulmonary disease involving allergic mechanisms, which historically affects patients with asthma or cystic fibrosis only. It is a source of respiratory decompensation. Its diagnosis requires the detection of total IgE, Aspergillus fumigatus-specific IgE, a chest X-ray or CT scan, Aspergillus fumigatus IgG and blood eosinophil measurement. These diagnostic criteria have several limitations in clinical practice. Indeed, radiographic abnormalities can be labile, and normal chest imaging therefore does not exclude the diagnosis but must be repeated. Similarly, blood eosinophils vary over time and are lowered by corticosteroid therapy. Finally, Aspergillus fumigatus specific IgE, when positive, does not allow us to distinguish simple sensitization from a true allergy to Aspergillus fumigatus.
- Status (registry)
- Completed
- Study type
- Observational
- Enrollment
- 67 (actual)
- First submitted
- 24 Jun 2025
- Start date
- 8 Jan 2022
- Primary completion date
- 2 Feb 2024
- Lead sponsor
- University Hospital, Rouen
- Diseases
- COPD
- NCT number
- NCT07055230
What you commit to
- Study type: Observational
- Participants enrolled: 67
- From 8 Jan 2022 to the primary completion date, 2 Feb 2024
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Patients receiving Omalizumab, Benralizumab, Mepolizumab, or Dupilumab, or whose treatment has been discontinued for less than 5.5 years.
- Patients receiving long-term oral corticosteroid therapy, or whose long-term treatment has been discontinued for less than 28 days. • Patients on long-term antifungal treatment, or whose long-term treatment was stopped less than 28 days ago.
Other illness
- Patients with another primary chronic pulmonary condition (asthma without COPD, cystic fibrosis, post-tuberculous fibrocavitary disease).
- Patients with hyper-IgE syndrome
- Patients with progressive parasitic disease.
Age
- Minors (\< 18 years old)
Other
- Patients not affiliated with Social Security
- Persons under court protection, adult guardianship, or curatorship.
- Patients with eosinophilic granulomatosis with polyangiitis.
- Patients with chronic pulmonary aspergillosis.
- Patients with invasive aspergillosis.
Who the study is looking for
- Adult patient (aged 18 years and older) being treated at Rouen University Hospital for chronic obstructive pulmonary disease and suspected of having ABPA
- Laboratory tests performed or prescribed prior to inclusion.
- Chest CT scan performed prior to inclusion.
- Pulmonary Function Test performed or prescribed prior to inclusion.
- Individual affiliated with a social security scheme
- Individual who has read and understood the information sheet and does not object to participating in the study
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| University Rouen Hospital Coordinator of this site? Confirm its status | Rouen | France | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.